Management of allergic rhinitis and sinusitis

Journal of Pharmacy Practice

Volumn 14, Issue 3, 2001, Pages 228-252

  Blake, Kathryn ^a   Larsen, Julie ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Allergic rhinitis; Antibiotics; Antihistamines; Decongestants; Intranasal corticosteroids; Sinusitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MONOCLONAL ANTIBODY; PENICILLIN DERIVATIVE; PHENYLPROPANOLAMINE;

ALGORITHM; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PENICILLIN ALLERGY; RISK FACTOR; SIDE EFFECT; SINUSITIS; TREATMENT PLANNING;

EID: 0034884337     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1106/PWNX-T6XM-YQG2-HBNH     Document Type: Article

References (124)

1. Prevalence of selected chronic conditions: United States, 1990-1992
2. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis
3. Allergic rhinitis: Epidemiology and natural history
4. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC)
5. A cost of illness study of allergic rhinitis in the United States
6. The economic impact of allergic rhinitis
7. The costs of allergic rhinitis
8. Economic outcomes for the treatment of allergic rhinitis
9. Costs of hay fever in the United States in 1990
10. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses
11. Economic outcomes of a targeted intervention program: The costs of treating allergic rhinitis patients
12. Mediators of inflammation and the inflammatory process
13. Pathogenesis of allergic rhinitis
14. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge
15. Leukotrienes in rhinitis
16. Rhinitis and Asthma
17. The pharmacology of α-adrenergic decongestants
18. Rhinitis
19. Inhibition of mediator release during the early reaction to antigen
20. Allergic rhinitis
21. The cells of the allergic response: Mast cells, basophils, and eosinophils
22. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator
23. The effects of antihistamines on cognition and performance
24. Comparative safety of H1 antihistamines
25. Occupational injuries and medication use
26. Treating the student with allergic rhinitis
27. Special considerations in the treatment of seasonal allergic rhinitis in adolescents: The role of antihistamine therapy
28. Sedating effects of AM/PM antihistamine dosing with evening chlorpheniramine and morning terfenadine
29. Diagnosis and management of rhinitis: Parameter documents of the joint task force on practice parameters in allergy, asthma, and immunology
30. Second-generation antihistamines: A comparative review
31. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis
32. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis
33. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis
34. Phenylpropanolamine and the risk of hemorrhagic stroke
35. A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis
36. Consensus statement on the treatment of allergic rhinitis
37. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials
38. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis
39. Use of nasal steroids in managing allergic rhinitis
40. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy
41. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily
42. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients
43. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: Further exploration of "as needed" use
44. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis
45. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis
46. Long-term safety of budesonide nasal aerosol: A 5.5-year follow-up study
47. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis
48. Nasal septal perforation associated with topical corticosteroid therapy
49. Nasal sprays and perforation of the nasal septum
50. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport
51. Adverse effects of benzalkonium chloride on the nasal mucosa: Allergic rhinitis and rhinitis medicamentosa
52. Preservation of nasal sprays
53. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity
54. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis
55. Systemic effects of intranasal steroids: An endocrinologist's perspective
56. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate
57. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids
58. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray
59. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma
60. Risk of cataract among users of intranasal corticosteroids
61. Mediators of allergic rhinitis
62. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis
63. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis
64. Recent advances in alternative therapies
65. Herbal interventions in asthma and allergy
66. Natural allergy remedies
67. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
68. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis
69. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis
70. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor
71. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
72. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis
73. The use of newer asthma and allergy medications during pregnancy
74. Pharmacokinetics of loratadine in patients with renal insufficiency
75. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire
76. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire
77. Current estimates from the National Health Interview Survey, 1995
78. Healthcare expenditures for sinusitis in 1996: Contributions of asthma, rhinitis, and other airway disorders
79. Perennial allergic rhinitis and chronic sinusitis: Correlation with rhinologic risk factors
80. Allergy and sinusitis
81. The health impact of chronic sinusitis in patients seeking otolaryngologic care
82. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis
83. Parameters for the diagnosis and management of sinusitis
84. Allergic and infectious pediatric sinusitis
85. Acute and chronic sinusitis in children
86. Correlation of allergy and severity of sinus disease
87. Inflammatory mechanisms in chronic sinusitis
88. Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis
89. The role of cytokines in rhinosinusitis
90. Cytokines in nasal polyposis, acute and chronic sinusitis
91. Immunologic defects in patients with refractory sinusitis
92. Pathophysiology of reactive airway disease and sinusitis
93. Management of sinusitis in the asthmatic patient
94. Improvement of bronchial hyperresponsiveness in asthmatic children treated for concomitant sinusitis
95. Complications of allergic rhinitis: Implications for sinusitis and asthma
96. Endoscopic sinus surgery improves pulmonary function in patients with asthma associated with chronic sinusitis
97. Long-term impact of functional endoscopic sinus surgery on asthma
98. Chronic sinus disease with associated reactive airway disease in children
99. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis
100. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
101. Clinical evaluation for sinusitis. Making the diagnosis by history and physical examination
102. Severity staging in chronic sinusitis: Are CT scan findings related to patient symptoms?
103. Relationship between patient-based descriptions of sinusitis and paranasal sinus computed tomographic findings
104. Patient knowledge of upper respiratory infections: Implications for antibiotic expectations and unnecessary utilization
105. Antibiotic prescribing for Canadian preschool children: Evidence of overprescribing for viral respiratory infections
106. Pharmacotherapy of acute sinusitis in children
107. Economic evaluation of antibacterials in the treatment of acute sinusitis
108. Short course antibiotic therapy for respiratory infections: A review of the evidence
109. Functional endoscopic sinus surgery: Evaluation, surgery, and follow-up of 250 patients
110. Sinusitis: Bench to bedside. Current findings, future directions
111. Effects of sinus surgery on asthma in aspirin triad patients
112. Follow-up study of pseudoephedrine users
113. Nasal nitric oxide
114. Inhibition of nitric oxide synthase by nasal decongestants
115. The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV)
116. Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis
117. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis
118. Effect of steroids on nasal inflammatory cells and cytokine profile
119. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases
120. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray
121. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children